NCT05029323|Unknown
Loading search results
Sponsor study identifier
interventional
500
1 country
1
Study Start
January 7, 2020
Actual (reported)Primary Completion
January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of the study is to compare the positivity rate associated with a novel simplified Tilt-Table (TT) test protocol versus the conventional TT protocol
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 7, 2020
Actual (reported)July 27, 2021
Actual (reported)August 31, 2021
Actual (reported)January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
HUTT positivity rate during passive phase
The study endpoint is the number of patients who experienced syncope during the passive phase of HUTT.
through study completion, an average of 1 year
HUTT positivity rate during active phase
The study endpoint is the number of patients who experienced syncope during the active phase of HUTT.
through study completion, an average of 1 year
The type of HUTT-induced syncope during passive phase
through study completion, an average of 1 year
The type of HUTT-induced syncope during active phase
through study completion, an average of 1 year
All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to "conventional" HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray.
All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to "fast" HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
University of Campania "Luigi Vanvitelli"
Naples, Italy
Vincenzo Russo, MD PhD
University of Campania Luigi Vanvitelli
First Submitted
July 27, 2021
First Posted
August 31, 2021
Study Start
January 7, 2020
Actual (reported)Primary Completion
January 7, 2023
Estimated (date passed)Pacemaker Effect With Closed Loop Sensor in Neuromodulated Syncope Refractory to Medical Therapy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 7, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 31, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: